Lisa Logie’s Post

1922 marked the first insulin injection for diabetes. In the century that has followed, clinical research has made significant strides, from novel insulin delivery methods to the artificial pancreas. This World Diabetes Day, join us in celebrating how far research has come, and visit our website to learn how you can become a partner in spreading the word about clinical trials. #researchascare #worlddiabetesday

What are the unmet needs in pulmonary arterial hypertension (PAH) care? Ronald Oudiz, MD, FACP, FACC, FCCP, addresses the current PAH landscape and examines emerging therapies. Watch the episode here: https://bit.ly/3JX894y #hypertension

SDRI's Research Scientist, Andrew Koutnik, PhD, joined forces with JDRF International representatives, and Jesse Ebadi, District Representative for Congressman Salud Carbajal, to discuss crucial initiatives for the diabetes community. The critical need to continue federal NIH funding to advance type 1 diabetes (T1D) research, lived experiences of T1D, and the critical need to lower insulin pricing for all were discussed. Together, we can make a difference and create a better tomorrow for all!

Six new #T1D research projects launch today! 🤩 Funded through the #Type1DiabetesGrandChallenge, the funding will accelerate the development of novel insulins. This vital #research the potential to transform life with #Type1Diabetes by keeping blood glucose levels more stable and reducing the mental burden of managing T1D. Four of the #research projects will accelerate the development of insulins that react to changing glucose levels. One study will create an ultrafast insulin that will bring us closer to fully closed-loop systems that don't need input from the user. The final project will combine insulin and glucagon into one molecule to combat hypos. 📰 Find out more: https://bit.ly/46Erm5K Steve Morgan Foundation Diabetes UK JDRF Australia Breakthrough T1D

OPEP devices are used therapeutically to aid airway clearance where excess mucus is a challenge, such as in bronchiectasis, cystic fibrosis and COPD. The mechanism of device action can differ greatly between different OPEP devices and therefore clinical data is important to demonstrate the effectiveness of each device. A clinically relevant laboratory metric such as the one utilized in this study can provide additional insights into likely differences in effectiveness. See the results here: https://lnkd.in/gN_7_EPX

July FDA Approvals Roundup: New Treatments Across Multiple Conditions July was a big month for FDA approvals, with significant advancements in the treatment of Alzheimer's and other conditions. Here's a quick look at the latest breakthroughs: Alzheimer's Disease: Kisunla (IV): Approved for early symptomatic Alzheimer's, offering hope for early-stage patients. Zunveyl (Oral): Cleared for mild-to-moderate Alzheimer's, providing a new oral option for patients. #FDAApprovals #AlzheimersTreatment #BiotechNews #PharmaInnovation #HealthcareAdvances

Currently in clinical trials, senolytics are an exciting, potentially new class of therapies that target #senescent cells and could change the way we approach chronic and inflammatory diseases.     Our #senolytic agent is designed to target and clear senescent cells in diabetic retinas, allowing the damaged tissue to heal itself and potentially restoring vision for patients living with #DME. See our scientific approach and recent clinical data outlined in Nature’s article here: https://bit.ly/3QPwlcZ  

🎉Proud to have shared our latest breakthrough with the esteemed halls of the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)!   🚀During this remarkable experience, I had the opportunity to present my poster titled "A Feasibility Study on a Bioimpedance Spectroscopy-Based Method for Insulin Bioavailability Measurement." 💡 The study focuses on a groundbreaking non-invasive approach for measuring insulin absorption in diabetic patients after insulin injection.  🩺 Adopting a real-time self-calibration method, the proposed approach represents a significant leap in personalized medicine, offering patients a more precise and less invasive method for managing diabetes. 🎯 You can find more information on the research here:  https://lnkd.in/d6hxSKp2 #ATTD #DiabetesResearch #MedicalInnovation #BioimpedanceSpectroscopy#ATTD2024 #InsulinMonitoring 🌐

The findings suggest that resistance training may have potential benefits for individuals undergoing inelastic compression therapy for chronic venous disease, as it can improve the effectiveness of compression therapy by enhancing interface pressure and reducing venous hypertension during ambulation. More information can be found in the study titled: "Effects of lower limb muscle strengthening on interface pressure in older adults undergoing inelastic compression: Randomized controlled clinical trial", authored by: Eduardo Simões Da Matta, Giovanni Mosti, Vanessa Silva Da Corralo, Luciano Branco de Quadros, Clodoaldo Antônio De Sá The study can be accessed at: https://lnkd.in/eMhxKxBX You can find further scientific publications in our publication database: https://lnkd.in/gMeMFs_V Furthermore, our newsletter shares information regarding the latest scientific publications involving L&R products. To subscribe to the newsletter, please register via the following link: https://lnkd.in/efFC4_hZ #LRMed #MedicalCompression #Medicalscience #pubmed #Science

Innovation is in our DNA. Our robust therapeutic portfolio is the result of keen insights into multiple disease states for which we’re developing potential treatments, including plasma and non-plasma solutions alike. The next wave of Grifols innovation has the potential to significantly transform #healthcare. Discover our key therapeutic areas. 👇 #WeAreHealthcare #healthcareinnovation